Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

Shashi Gujar; Jonathan G. Pol; Youra Kim; Guido Kroemer

doi:10.1080/2162402X.2020.1794424

Repurposing CD8⁺ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

Shashi Gujar, Jonathan G. Pol, Youra Kim, Guido Kroemer

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

Abstract

The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8⁺ T cells for cancer immunotherapy strategies.

Original language	English
Article number	1794424
Journal	OncoImmunology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2020.1794424
Publication status	Published - 1 Jan 2020

Keywords

CD8 T cell epitopes
SARS-CoV-2
antigen spreading
antiviral immunity
cancer immunotherapy

Access to Document

10.1080/2162402X.2020.1794424

Cite this

@article{ace2b9bf65d8478891d1278452840ba7,

title = "Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?",

abstract = "The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.",

keywords = "CD8 T cell epitopes, SARS-CoV-2, antigen spreading, antiviral immunity, cancer immunotherapy",

author = "Shashi Gujar and Pol, {Jonathan G.} and Youra Kim and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} 2020, {\textcopyright} 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2020",

month = jan,

day = "1",

doi = "10.1080/2162402X.2020.1794424",

language = "English",

volume = "9",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy

T2 - a positive aspect of the COVID-19 pandemic?

AU - Gujar, Shashi

AU - Pol, Jonathan G.

AU - Kim, Youra

AU - Kroemer, Guido

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.

AB - The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.

KW - CD8 T cell epitopes

KW - SARS-CoV-2

KW - antigen spreading

KW - antiviral immunity

KW - cancer immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85088043873&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2020.1794424

DO - 10.1080/2162402X.2020.1794424

M3 - Review article

C2 - 32923158

AN - SCOPUS:85088043873

SN - 2162-4011

VL - 9

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 1794424